<p>美国银行证券分析师 Jason Zemansky 今天对 Lyell Immunopharma 维持了卖出评级，并设定了 12.00 美元的目标价。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>根据 TipRanks，Zemansky 是一位五星级分析师，平均回报率为 21.3%，成功率为 58.82%。Zemansky 覆盖医疗保健行业，专注于 Biogen、Cytokinetics 和 BridgeBio Pharma 等股票。</p>
<p>市场普遍认为，Lyell Immunopharma 的分析师共识评级为适度买入，平均目标价为 36.80 美元。</p>

LYEL

<p>美国银行证券分析师 Jason Zemansky 重申了对 Lyell Immunopharma（LYEL）的卖出评级，目标价为 12.00 美元。Zemansky 是一位五星级分析师，平均回报率为 21.3%，成功率为 58.82%。对 Lyell Immunopharma 的整体分析师共识为适度买入，平均目标价为 36.80 美元</p>

<p>Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Lyell Immunopharma today and set a price target of $12.00.</p>
<div class="lb-trans"><p>美国银行证券分析师 Jason Zemansky 今天对 Lyell Immunopharma 维持了卖出评级，并设定了 12.00 美元的目标价。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>According to TipRanks, Zemansky is a 5-star analyst with an average return of 21.3% and a 58.82% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Biogen, Cytokinetics, and BridgeBio Pharma.</p>
<div class="lb-trans"><p>根据 TipRanks，Zemansky 是一位五星级分析师，平均回报率为 21.3%，成功率为 58.82%。Zemansky 覆盖医疗保健行业，专注于 Biogen、Cytokinetics 和 BridgeBio Pharma 等股票。</p>
</div><p>The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lyell Immunopharma with a $36.80 average price target.</p>
<div class="lb-trans"><p>市场普遍认为，Lyell Immunopharma 的分析师共识评级为适度买入，平均目标价为 36.80 美元。</p>
</div>

Bank of America Securities Reaffirms Their Sell Rating on Lyell Immunopharma (LYEL)

Tip Ranks

Lyell Immunopharma

美国银行

Biogen

细胞动力

Bridgebio Pharma

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美国银行证券重申了对 Lyell Immunopharma（LYEL）的卖出评级